Recent news suggests President Donald Trump is considering a significant policy shift. He is reportedly weighing an executive order. This order would reclassify marijuana. It would move cannabis from Schedule I to Schedule III. Such a move would ease federal restrictions. This news has boosted cannabis stocks considerably. It is a trending topic in financial news.
The Schedule I classification means marijuana has a high potential for abuse. It also means no accepted medical use. Schedule III drugs have a moderate to low potential for abuse. They also have accepted medical uses. Examples include ketamine and Tylenol with codeine.
This rescheduling process has a history. The Biden administration initiated steps to reexamine marijuana’s federal status. Federal health regulators recommended moving cannabis to Schedule III in August 2023. However, this process stalled out under Biden. Some reports suggest resistance within the DEA may have contributed to delays.
Now, reports indicate Trump is taking up this initiative. He reportedly discussed the matter on a call. This call included House Speaker Mike Johnson. It also included industry executives and health officials. Trump cannot unilaterally reschedule the drug. However, he can direct the Justice Department. The exact plan is not yet finalized. Trump could still change his mind. A White House official stated no final decisions have been made.
This potential reclassification could deeply impact the cannabis industry. It is a $32 billion sector. A major benefit would be tax relief. Currently, Section 280E of the tax code burdens cannabis businesses. Rescheduling could allow normal business deductions. This would improve profitability. It could also ease barriers to research and banking.
Cannabis stocks reacted sharply to this news. Major companies saw significant gains. Tilray Brands, Canopy Growth, and Aurora Cannabis experienced notable jumps. SNDL Inc and Cronos Group also saw increased share prices. ETFs focused on cannabis also trended higher.
However, this potential change is not full legalization. Rescheduling to Schedule III would not make cannabis federally legal. State markets will still conflict with federal law. It would not create a comprehensive national framework. The Drug Enforcement Administration (DEA) still has a formal rulemaking process to complete.
In summary, the prospect of marijuana’s rescheduling under Trump has invigorated the cannabis market. It offers potential financial and research benefits. Yet, the ultimate decision remains pending. The industry and investors watch closely for official confirmation on this developing cannabis news.
